Galapagos changed course earlier this year, announcing it no longer wanted to focus on cell therapy and would seek buyers for this business. After shopping around the assets for months, Galapagos ...

Cutting-edge gene editing technology could eradicate Down syndrome, according to Japanese scientists. Down syndrome, which causes a range of developmental differences and affects 1 in 700 newborns in ...

Galapagos (GLPG) announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its board of directors has decided to initiate the wind ...

AMSTERDAM, Oct 21 (Reuters) - Biotechnology firm Galapagos (GLPG.AS), opens new tab said on Tuesday it would wind down its cell therapy business after attempts to sell it were unsuccessful, affecting ...

Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium; ...

Children with Down’s syndrome have a 150-fold increased risk of developing leukaemia than those without the condition. Now, an in-depth investigation has revealed that changes to genome structures in ...